Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Medically reviewed by Soma Mandal, MD Petechiae are tiny red, purple, or brown spots on your skin, inside of your mouth, or ...

Democrats are calling on Treasury Secretary Scott Bessent to cancel his stop work order for the Consumer Financial Protection Bureau (CFPB) after employees with Elon Musk’s Department of ...

Search Engine Land » PPC » Google Ads optimization: What to stop, start, and continue in 2025 Chat with SearchBot Please note that your conversations will be recorded. Early this year ...

Blood pressure medications are usually taken for life. However, some people can stop taking them by addressing those underlying causes of high blood pressure (hypertension) that can be changed, such ...

Andexxa (andexanet alfa) is approved for the reversal of anticoagulation by Factor Xa inhibitors – Bayer/Johnson & Johnson's Xarelto (rivaroxaban) and Pfizer/Bristol-Myers Squibb's Eliquis ...

Bayer is sufficiently satisfied with the data to press ahead with its phase 3 programme, as it looks for a successor to Johnson & Johnson-partnered anticoagulant Xarelto (rivaroxaban), its biggest ...

Does your Mac slow to a crawl thanks to apps that spring to life upon startup? Here's how to disable and manage startup items to stop them in their tracks.

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.